A New Era: Apotex Gets Fresh Leadership As SK Completes Acquisition
Industry Veteran Allan Oberman Takes The Reins As CEO Of Canadian Generics Giant
As SK Capital Partners completes its acquisition of Apotex, generics industry veteran Allan Oberman has been named as the new president and CEO of the Canadian giant, replacing Jeff Watson who will remain on the company’s board.
You may also be interested in...
Executive changes at both Viatris and Teva in 2023 saw the companies shift their focus towards the innovator industry. Plus, trade groups saw some significant personnel shakeups, Alvotech expressed hope that new hires would help to resolve manufacturing approval issues, Biocon made changes to its management structure, and more.
Partners Apotex and Ambio have announced approval of a second US teriparatide generic from the FDA, adding another Forteo rival to the market and removing hopes that Teva’s recently approved first generic could benefit from 180 days of market exclusivity. Further competition is also in the works with Amphastar awaiting FDA action on a further teriparatide ANDA.
The IGBA has named the AAM’s David Gaugh as its chair for the remained of 2023, following the recent departure of Jonathan Kimball. At the same time, the international generics and biosimilars association has added two recently-appointed off-patent industry CEOs to its advisory committee, representing Apotex And Viatris.